Instil Bio (TIL) Stock Price, News & Analysis

Company Overview

Instil Bio, Inc. is a clinical-stage biotechnology company focused on developing novel T-cell therapies for the treatment of cancer. The company’s research centers on tumor-infiltrating lymphocytes (TILs), immune cells that can recognize and attack cancer cells within tumors.

Instil Bio is developing engineered TIL programs intended to improve the ability of these cells to persist, function, and target solid tumors. Its pipeline has included investigational therapies such as ITIL-306, an engineered TIL product designed to target CD70-expressing cancers, along with other early-stage cell therapy candidates.

The company was founded in 2015 and became a publicly traded company in 2021. Instil Bio is headquartered in Dallas, Texas, and conducts research and development through its biotechnology operations. Its therapies remain investigational and are subject to clinical and regulatory evaluation.

Key Stats

• Today's Range: $6.12 to $6.50
• 50-Day Range: $5.57 to $7.82
• 52-Week Range: $5.56 to $14.87
• Volume: 21,039 shs
• Average Volume: 51,441 shs
• Market Capitalization: $41.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Reduce

Instil Bio Stock Analysis - MarketRank™

Instil Bio scored higher than 32% of companies evaluated by MarketBeat, and ranked 779th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Reduce

Consensus Rating

Instil Bio has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Instil Bio has a consensus price target of $7.00, representing about 13.6% upside from its current price of $6.16.

Amount of Analyst Coverage

Instil Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Instil Bio is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Instil Bio is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Instil Bio has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.04% of the float of Instil Bio has been sold short.

Short Interest Ratio / Days to Cover

Instil Bio has a short interest ratio ("days to cover") of 2.28, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Instil Bio has recently increased by 6.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Instil Bio does not currently pay a dividend.

Dividend Growth

Instil Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Instil Bio has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Instil Bio this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Instil Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

47.00% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/13/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TIL
• CIK: 1789769
• Web: www.tillcap.com
• Phone: 972-499-3350
• Fax: N/A
• Employees: 410
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Instil Bio: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +13.6%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$71.37 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.78%
• Return on Assets: -14.89%

Debt

• Debt-to-Equity Ratio: 0.79
• Current Ratio: 21.67
• Quick Ratio: 21.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.79 per share
• Price / Book: 0.37

Miscellaneous

• Outstanding Shares: 6,780,000
• Free Float: 3,594,000
• Market Cap: $41.76 million
• Optionable: No Data
• Beta: 1.93